MARGINAL developments
to drugs are justifying patents
allowing for artificially high drug
prices in the US, according to a
new study in the Journal of the
American Medical Association.
Brand-name drugs with patents
that grant exclusivity account for
about 72% of drug spending, even
though they are only about 10% of
all prescriptions dispensed, with
unjustifiable patent extensions
based on minor drug form or
delivery system changes, the
authors claimed.The above article was sent to subscribers in Pharmacy Daily's issue from 24 Aug 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Aug 16
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
THE University of South Australia has released a new study to help healthcare workers better support women with persistent pelvic pain, including symptoms that are suggestive of gynaecological, lower urinary tract, bowel, sexual, and pelvic floor dysfunction.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.